Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 5—May 2017
Research

Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection

Matthew H. CollinsComments to Author , Eileen McGowan, Ramesh Jadi, Ellen Young, Cesar A. Lopez, Ralph S. Baric, Helen M. Lazear, and Aravinda M. de SilvaComments to Author 
Author affiliations: University of North Carolina, Chapel Hill, North Carolina, USA

Main Article

Figure 2

Schematic of the method used for depletion of human serum with DENV antigen to distinguish Zika virus–specific from cross-reactive flavivirus antibodies. Serum was incubated with DENV-1 and DENV-2 coated on polystyrene beads, enabling removal of DENV-specific and cross-reactive antibodies. DENV, dengue virus.

Figure 2. Schematic of the method used for depletion of human serum with DENV antigen to distinguish Zika virus–specific from cross-reactive flavivirus antibodies. Serum was incubated with DENV-1 and DENV-2 coated on polystyrene beads, enabling removal of DENV-specific and cross-reactive antibodies. DENV, dengue virus.

Main Article

Page created: April 14, 2017
Page updated: April 14, 2017
Page reviewed: April 14, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external